Therapeutic Biological Products
Mailing Address for Required Postmarketing Adverse Experience Information

All postmarketing adverse experience information required under 21 CFR 600.80 (Postmarketing 15-day "alert Reports", Postmarketing 15-day "Alert reports"-followup, and Periodic Adverse Experience Reports) shall be sent to:

Central Document Room
Center for Drug Evaluation and Research
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD 20705-1266

     Back to Index

Date created: October 9, 2003

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page

FDA/Center for Drug Evaluation and Research